The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
In light of the update from the company that market Atezolizumab, NICE will now stop the scoping exercise. Please accept our apologies for any inconvenience.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6218 |
Project Team
| Project lead | Emily Richards |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 May 2024 | Suspended. The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. In light of the update from the company that market Atezolizumab, NICE will now stop the scoping exercise. Please accept our apologies for any inconvenience. |
| 22 March 2024 - 09 April 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6218 |
| 22 March 2024 | In progress. Scoping commencing |
| 22 November 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual